Found 8 results
Author [ Title(Desc)] Type Year
Filters: First Letter Of Title is S and Author is Fast, P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
F. M. Kibengo, Ruzagira, E., Katende, D., Bwanika, A. N., Bahemuka, U., Kamali, A., Haberer, J. E., Bangsberg, D. R., Barin, B., Rooney, J. F., Mark, D., Chetty, P., Fast, P., and Priddy, F. H., Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial, PLoS One, vol. 8, p. e74314, 2013.
G. Mutua, Sanders, E., Mugo, P., Anzala, O., Haberer, J. E., Bangsberg, D., Barin, B., Rooney, J. F., Mark, D., Chetty, P., Fast, P., and Priddy, F. H., Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers, PLoS One, vol. 7, p. e33103, 2012.
F. Nakwagala, Birungi, J., Schmidt, C., Nanvubya, A., Konde, C., Hughes, P., Mugisha, E., Johnson, B., Muluubya, A., Nielsen, L., Gilmour, J., Gibiansky, L., Smith, C., Fast, P., and Kaleebu, P., Safety and immunogenicity of HIV-1 clade A vaccines in healthy, HIV uninfected adult Ugandan volunteers, 2004.
E. Vardas, Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., McIntyre, J., Gray, G., Bogoshi, M., Mayaphi, S., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., and Dally, L., Safety and Immunogenicity of MVA.HIVA by 3 Different Routes, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
W. Jaoko, Kayitenkore, K., G Manyonyi, O., Karita, E., Schmidt, C., Fast, P., Komaroff, W., Cooper, A., Boaz, M., Gilmour, J., Dally, L., Ho, M., Smith, C., and Graham, B., Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
G. Mutua, Hanke, T., Fast, P., Hannaman, D., Chinyenze, K., Oino, G., Sajabi, R., Verlinde, C., Barin, B., Reilly, M., and Jaoko, W., Safety and Tolerability of pSG2.HIVconsv DNA MVA.HIVconsv and Ad35-GRIN Prime-Boost Combinations Administered to Healthy HIV-Uninfected Kenyan Adults, in HIV R4P 2016, Chicago, IL, 2016.
S. Vasan, Hurley, A., Schlesinger, S., Hannaman, D., Gardiner, D., Dugin, D., Huang, Y., Andersen, J., Caskey, M., Evans, C., Dolter, K., Schmidt, C., Fast, P., and Ho, D., Safety, Tolerability, and Acceptability of Electroporation to Deliver ADVAX, a Clade C/B’ DNA-Based Candidate HIV-1 Vaccine, to Healthy Volunteers, in AIDS Vaccine 2008 Conference, Cape Town, South Africa, 2008.
B. S. Peters, Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J., Bogoshi, M., G Manyonyi, O., Dally, L., Klavinskis, L., Farah, B., Tarragona, T., Bart, P. - A., Robinson, A., Pieterse, C., Stevens, W., Thomas, R., Barin, B., and Bwayo, J. [..], Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity, Vaccine, vol. 25, pp. 2120-2127, 2007.